

Recent Report Study Explores Melanoma Pipeline Review, H2 2018

PUNE, MAHARASHTRA, INDIA,
February 12, 2018 /EINPresswire.com/ --

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Melanoma Global Clinical Trials Review, H2, 2018"

Melanoma

Overview

Clinical trial report, "Melanoma Global Clinical Trials Review, H2, 2018" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/2879284-melanoma-global-clinical-trials-review-h2-2017>

Top Companies mentioned

Bristol-Myers Squibb Co

Hoffmann-La Roche Ltd
Merck & Co Inc

Novartis AG

GlaxoSmithKline Plc

AstraZeneca Plc



WISE GUY
REPORTS

AKASH ANAND
ASST.MANAGER - BUSINESS DEVELOPMENT

✉ sales@wiseguyreports.com
☎ Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <http://twitter.com/WiseGuyReports>
📘 <http://www.facebook.com/Wiseguyreports-100907869213183/?fref=ts>

Melanoma

Pfizer Inc

Sarah Cannon Research Institute LLC

Melanoma - Competitive Analysis

Key players are making innovative developments in Melanoma industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The report provides a snapshot of the global therapeutic landscape of Melanoma

The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Melanoma therapeutics and enlists all their major and minor projects

The report assesses Systemic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/2879284-melanoma-global-clinical-trials-review-h2-2017>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.